(MRM) Medirom Healthcare - Ratings and Ratios
Relaxation, Therapy, Salon, Digital Health, Beauty
Description: MRM Medirom Healthcare
MEDIROM Healthcare Technologies Inc. is a Japanese company that offers a range of holistic health services through its subsidiaries, operating in three main segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty. Its Relaxation Salon segment provides various therapies, including finger-pressure style bodywork and posture alignment, under brands such as Re.Ra.Ku and Ruam Ruam.
The companys Digital Preventative Healthcare segment leverages technology, including a health monitoring smartphone application called Lav and a fitness tracker called MOTHER Bracelet, to offer preventative healthcare services, including government-sponsored health guidance programs. Meanwhile, its Luxury Beauty segment operates high-end hair salons under the ZACC brand. MEDIROM also provides training for its franchise owners and staff through Re.Ra.Ku College.
With a presence in Japan and a diverse range of services, MEDIROM Healthcare Technologies Inc. is well-positioned to capitalize on the growing demand for holistic health and wellness services. The companys use of technology in its Digital Preventative Healthcare segment is particularly noteworthy, as it allows for greater accessibility and scalability.
Analyzing the available data, we can see that MRMs stock has experienced significant volatility, with a 52-week high of $6.07 and a low of $0.36. The current price of $1.50 is above its 20-day and 50-day simple moving averages, indicating a potential uptrend. However, the stock is below its 200-day SMA, which may indicate a longer-term downtrend.
Using the available technical and fundamental data, a forecast for MRMs stock price can be made. Given the companys negative P/E ratio and RoE of -93.38, it is clear that MRM is currently unprofitable. However, if the company can successfully execute its business plan and achieve profitability, the stock may experience a significant rebound. Based on the current SMA20 and SMA50, a potential target price could be around $1.80-$2.00, representing a 20-33% increase from the current price. However, this is contingent on the companys ability to achieve profitability and improve its financial metrics.
MRM Stock Overview
| Market Cap in USD | 13m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2020-12-29 |
MRM Stock Ratings
| Growth Rating | -70.7% |
| Fundamental | 40.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -61.2% |
| Analyst Rating | 5.0 of 5 |
MRM Dividends
Currently no dividends paidMRM Growth Ratios
| Growth Correlation 3m | 51.6% |
| Growth Correlation 12m | -30% |
| Growth Correlation 5y | -92.3% |
| CAGR 5y | -33.19% |
| CAGR/Max DD 3y | -0.35 |
| CAGR/Mean DD 3y | -1.23 |
| Sharpe Ratio 12m | -1.57 |
| Alpha | -71.54 |
| Beta | 0.762 |
| Volatility | 177.43% |
| Current Volume | 79.8k |
| Average Volume 20d | 259.1k |
| Stop Loss | 1.6 (-11.1%) |
| Signal | -1.00 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (854.5m TTM) > 0 and > 6% of Revenue (6% = 820.6m TTM) |
| FCFTA -0.23 (>2.0%) and ΔFCFTA -12.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -10.79% (prev -20.83%; Δ 10.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.17 (>3.0%) and CFO -1.36b <= Net Income 854.5m (YES >=105%, WARN >=100%) |
| Net Debt (3.63b) to EBITDA (493.1m) ratio: 7.36 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (5.85m) change vs 12m ago 19.85% (target <= -2.0% for YES) |
| Gross Margin 26.18% (prev 25.22%; Δ 0.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 183.1% (prev 126.3%; Δ 56.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.49 (EBITDA TTM 493.1m / Interest Expense TTM 49.9m) >= 6 (WARN >= 3) |
Altman Z'' -1.04
| (A) -0.18 = (Total Current Assets 2.71b - Total Current Liabilities 4.18b) / Total Assets 8.09b |
| (B) 0.03 = Retained Earnings (Balance) 229.0m / Total Assets 8.09b |
| (C) -0.00 = EBIT TTM -24.5m / Avg Total Assets 7.47b |
| (D) 0.08 = Book Value of Equity 581.7m / Total Liabilities 6.90b |
| Total Rating: -1.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 40.15
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -30.59% = -5.0 |
| 3. FCF Margin -13.87% = -5.20 |
| 4. Debt/Equity 4.96 = -2.50 |
| 5. Debt/Ebitda 9.38 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE 199.4% = 2.50 |
| 8. Rev. Trend 34.61% = 1.73 |
| 9. Rev. CAGR 83.07% = 2.50 |
| 10. EPS Trend 24.74% = 0.62 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of MRM shares?
Over the past week, the price has changed by -7.22%, over one month by -15.09%, over three months by +17.65% and over the past year by -53.85%.
Is Medirom Healthcare a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRM is around 1.32 USD . This means that MRM is currently overvalued and has a potential downside of -26.67%.
Is MRM a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MRM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.3 | 192.2% |
| Analysts Target Price | 5.3 | 192.2% |
| ValueRay Target Price | 1.5 | -17.8% |
Last update: 2025-09-08 04:45
MRM Fundamental Data Overview
CCE Cash And Equivalents = 335.6m JPY (Cash And Short Term Investments, last quarter)
P/E Trailing = 8.6316
P/S = 0.0016
P/B = 2.0551
Beta = 0.918
Revenue TTM = 13.68b JPY
EBIT TTM = -24.5m JPY
EBITDA TTM = 493.1m JPY
Long Term Debt = 2.72b JPY (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.91b JPY (from shortTermDebt, last quarter)
Debt = 4.63b JPY (Calculated: Short Term 1.91b + Long Term 2.72b)
Net Debt = 3.63b JPY (from netDebt column, last quarter)
Enterprise Value = 6.20b JPY (1.91b + Debt 4.63b - CCE 335.6m)
Interest Coverage Ratio = -0.49 (Ebit TTM -24.5m / Interest Expense TTM 49.9m)
FCF Yield = -30.59% (FCF TTM -1.90b / Enterprise Value 6.20b)
FCF Margin = -13.87% (FCF TTM -1.90b / Revenue TTM 13.68b)
Net Margin = 6.25% (Net Income TTM 854.5m / Revenue TTM 13.68b)
Gross Margin = 26.18% ((Revenue TTM 13.68b - Cost of Revenue TTM 10.10b) / Revenue TTM)
Tobins Q-Ratio = 10.66 (Enterprise Value 6.20b / Book Value Of Equity 581.7m)
Interest Expense / Debt = 1.08% (Interest Expense 49.7m / Debt 4.63b)
Taxrate = -189.6% (set to none) (-90.5m / 47.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 0.65 (Total Current Assets 2.71b / Total Current Liabilities 4.18b)
Debt / Equity = 4.96 (Debt 4.63b / last Quarter total Stockholder Equity 933.3m)
Debt / EBITDA = 9.38 (Net Debt 3.63b / EBITDA 493.1m)
Debt / FCF = -2.44 (Debt 4.63b / FCF TTM -1.90b)
Total Stockholder Equity = 428.6m (last 4 quarters mean)
RoA = 10.56% (Net Income 854.5m, Total Assets 8.09b )
RoE = 199.4% (Net Income TTM 854.5m / Total Stockholder Equity 428.6m)
RoCE = -0.78% (Ebit -24.5m / (Equity 428.6m + L.T.Debt 2.72b))
RoIC = unknown (NOPAT none, Invested Capital 2.03b, Ebit -24.5m)
WACC = unknown (E(1.91b)/V(6.54b) * Re(8.82%)) + (D(4.63b)/V(6.54b) * Rd(1.08%) * (1-Tc(none)))
Shares Correlation 3-Years: 41.49 | Cagr: 1.66%
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -1.90b)
EPS Correlation: 24.74 | EPS CAGR: 0.0% | SUE: 1.87 | # QB: True
Revenue Correlation: 34.61 | Revenue CAGR: 83.07%
Additional Sources for MRM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle